Clinic Software
About
OncoPrecision is a precision oncology company engineering first-in-class antibody-drug conjugates (ADCs) and bispecific antibodies for hard-to-treat cancers. We start where other drugs fail — studying how cancer cells evade treatment — then engineer precision weapons to exploit those vulnerabilities. By combining our Patient Micro-Avatars™ with AI-driven target validation across billions of phenotypic data points, our discovery engine surfaces biology that population-level datasets miss — giving every program a structural advantage from day one. Our lead program, ONC001, is a first-in-class CD64-targeting ADC designed to eliminate leukemic monocytes and tumor-associated macrophages. ONC001 is currently advancing through IND-enabling studies.
Product
- Value proposition
- OncoPrecision is an oncology therapeutics company developing precision medicines guided by real patient biology, leveraging AI-driven discovery and patient-derived models to create targeted therapies with higher probabilities of clinical success.
- Target customers
- Pharma/Biotech companies, research partners, healthcare providers seeking precision oncology therapeutics
Founders
- Candelaria Llorens De Los Ríos — Co-Founder & Head of Operations
- Gastón Soria — Co-Founder & CSO
- Gerardo Gatti — Co-Founder & Head of Clinical Research
- Tarek Ali Zaki — Co-Founder & CEO
Categories
Products
Key features
Technologies
Target conditions
Care settings
News
- Org of the Week: OncoPrecision | The Org · 2025-04-22T16:00:00.000Z
- OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting · 2025-12-01T15:17:00.000Z
- OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting · 2025-12-01T15:17:00.000Z
- [PDF] Ecosystem Report 2025 - Startup Genome
- OncoPrecision Announces Oral Presentation of ONC001, a First-in-Class CD64-Targeting ADC for Monocytic Leukemia, at the 67th ASH Annual Meeting · 2025-12-01T15:17:00.000Z
